Vestal Point Capital Acquires $181.80 Million Stake in Terns Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TERN?
Source: Fool
- New Investment Disclosure: On February 17, 2026, Vestal Point Capital disclosed a new position by acquiring 4.5 million shares of Terns Pharmaceuticals worth $181.80 million, indicating strong confidence in the company's future growth prospects.
- Holding Value Analysis: This acquisition positions Terns as 6.7% of Vestal's portfolio, making it one of the top five holdings, reflecting the company's potential and market recognition in the biopharmaceutical sector.
- Stock Performance: As of Monday, Terns' shares were priced at $46.07, soaring 1,300% over the past year, significantly outperforming the S&P 500's 19% gain, highlighting strong market demand for its small-molecule therapies.
- Robust Financial Position: Terns boasts approximately $1 billion in cash and marketable securities, sufficient to fund operations and potential clinical milestones, indicating a strong financial foundation for a clinical-stage biotech and enhancing investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TERN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TERN
Wall Street analysts forecast TERN stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 46.520
Low
35.00
Averages
54.22
High
60.00
Current: 46.520
Low
35.00
Averages
54.22
High
60.00
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vestal Point Capital Acquires $181.80 Million Stake in Terns Pharmaceuticals
- New Investment Disclosure: On February 17, 2026, Vestal Point Capital disclosed a new position by acquiring 4.5 million shares of Terns Pharmaceuticals worth $181.80 million, indicating strong confidence in the company's future growth prospects.
- Holding Value Analysis: This acquisition positions Terns as 6.7% of Vestal's portfolio, making it one of the top five holdings, reflecting the company's potential and market recognition in the biopharmaceutical sector.
- Stock Performance: As of Monday, Terns' shares were priced at $46.07, soaring 1,300% over the past year, significantly outperforming the S&P 500's 19% gain, highlighting strong market demand for its small-molecule therapies.
- Robust Financial Position: Terns boasts approximately $1 billion in cash and marketable securities, sufficient to fund operations and potential clinical milestones, indicating a strong financial foundation for a clinical-stage biotech and enhancing investor confidence.
See More
Vestal Point Acquires 4.5 Million Shares of Terns Pharmaceuticals
- New Investment Position: Vestal Point Capital acquired 4.5 million shares of Terns Pharmaceuticals in Q4 2026, totaling $181.80 million, establishing a new stake that reflects confidence in the biopharmaceutical sector.
- AUM Proportion: This acquisition represents 6.7% of Vestal Point's assets under management, indicating a strategic commitment to biotechnology and optimism about future growth potential.
- Clinical Stage Advantage: Terns Pharmaceuticals focuses on developing small-molecule therapies for NASH and metabolic diseases, with a pipeline that includes multiple candidates in Phase I and II trials, showcasing its potential to address significant unmet medical needs.
- Financial Stability: Terns boasts a strong balance sheet with approximately $1 billion in cash and marketable securities, sufficient to fund operations and clinical milestones well into the next decade, which enhances investor confidence.
See More
Surge in Options Volume for Terns and Super Micro
- Terns Options Volume: Terns Pharmaceuticals Inc has seen an options volume of 16,978 contracts today, representing approximately 1.7 million underlying shares, which accounts for 89.7% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest in its future performance.
- High Strike Contracts: Particularly notable is the $50 strike call option for TERN, with 15,238 contracts traded today, equating to about 1.5 million shares, suggesting strong bullish sentiment among investors at this price level.
- Super Micro Options Volume: Super Micro Computer Inc has recorded an options volume of 215,773 contracts today, representing approximately 21.6 million underlying shares, which is 86.2% of its average daily trading volume of 25 million shares over the past month, reflecting high investor activity in its stock.
- Significant Contracts: For SMCI, the $34.50 strike call option has seen 27,205 contracts traded today, amounting to around 2.7 million shares, indicating strong market interest at this price point, which could influence future stock price movements.
See More
Boxer Capital Acquires New Stake in Terns Pharmaceuticals
- New Investment Disclosure: On February 17, 2026, Boxer Capital Management disclosed its new investment in Terns Pharmaceuticals, acquiring 375,000 shares valued at approximately $15.15 million, indicating strong confidence in the company's future prospects.
- Significant Ownership: This acquisition brings Boxer Capital's stake in Terns to 3.32%, representing a notable position within its $456.88 million in 13F reportable assets under management, reflecting a strategic focus on the biopharmaceutical sector.
- Outstanding Stock Performance: As of February 17, 2026, Terns' shares were priced at $39.58, marking an impressive 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, showcasing strong market recognition of its small-molecule therapies.
- Broad Market Potential: Terns focuses on developing small-molecule therapies targeting non-alcoholic steatohepatitis (NASH) and obesity, with several candidates in clinical trials, poised for value creation through commercialization or out-licensing, addressing urgent market needs for new therapies.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Share Reduction Transaction: According to a SEC filing dated February 17, 2026, ORBIMED Advisors LLC sold 5,409,671 shares of Terns Pharmaceuticals for approximately $125 million, indicating a potential decrease in confidence regarding the company's future prospects.
- Holding Changes: Following this sale, ORBIMED retains 2,153,300 shares of Terns, with a value decrease of $30.20 million, reflecting fluctuations in market expectations for its clinical pipeline.
- Market Performance: As of February 17, 2026, Terns' stock price stood at $39.58, marking an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, showcasing strong market confidence in its biotech potential.
- Investor Focus: With upcoming clinical data releases, investors should monitor Terns' cash flow and trial results to assess whether its pipeline justifies the current high valuation, especially since robust data is crucial for sustaining valuation in the biotech sector.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Stake Reduction Size: ORBIMED Advisors LLC disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Terns Pharmaceuticals by 5,409,671 shares, with an estimated transaction size of $125.01 million, reflecting a cautious outlook on the company's future prospects.
- Position Value Change: Following this transaction, ORBIMED's position in Terns decreased to 2,153,300 shares, with a value drop of $30.20 million, indicating the market's sensitivity to fluctuations in the company's stock price.
- Asset Management Proportion: After the reduction, Terns now represents 1.78% of ORBIMED's reportable AUM, falling outside the top five holdings, which suggests a diminished significance in the investment portfolio.
- Market Performance Comparison: As of February 17, 2026, Terns' stock price stood at $39.58, reflecting an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, demonstrating strong market confidence in its clinical pipeline.
See More
Vestal Point Capital Acquires $181.80 Million Stake in Terns Pharmaceuticals
- New Investment Disclosure: On February 17, 2026, Vestal Point Capital disclosed a new position by acquiring 4.5 million shares of Terns Pharmaceuticals worth $181.80 million, indicating strong confidence in the company's future growth prospects.
- Holding Value Analysis: This acquisition positions Terns as 6.7% of Vestal's portfolio, making it one of the top five holdings, reflecting the company's potential and market recognition in the biopharmaceutical sector.
- Stock Performance: As of Monday, Terns' shares were priced at $46.07, soaring 1,300% over the past year, significantly outperforming the S&P 500's 19% gain, highlighting strong market demand for its small-molecule therapies.
- Robust Financial Position: Terns boasts approximately $1 billion in cash and marketable securities, sufficient to fund operations and potential clinical milestones, indicating a strong financial foundation for a clinical-stage biotech and enhancing investor confidence.
See More
Vestal Point Acquires 4.5 Million Shares of Terns Pharmaceuticals
- New Investment Position: Vestal Point Capital acquired 4.5 million shares of Terns Pharmaceuticals in Q4 2026, totaling $181.80 million, establishing a new stake that reflects confidence in the biopharmaceutical sector.
- AUM Proportion: This acquisition represents 6.7% of Vestal Point's assets under management, indicating a strategic commitment to biotechnology and optimism about future growth potential.
- Clinical Stage Advantage: Terns Pharmaceuticals focuses on developing small-molecule therapies for NASH and metabolic diseases, with a pipeline that includes multiple candidates in Phase I and II trials, showcasing its potential to address significant unmet medical needs.
- Financial Stability: Terns boasts a strong balance sheet with approximately $1 billion in cash and marketable securities, sufficient to fund operations and clinical milestones well into the next decade, which enhances investor confidence.
See More
Surge in Options Volume for Terns and Super Micro
- Terns Options Volume: Terns Pharmaceuticals Inc has seen an options volume of 16,978 contracts today, representing approximately 1.7 million underlying shares, which accounts for 89.7% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest in its future performance.
- High Strike Contracts: Particularly notable is the $50 strike call option for TERN, with 15,238 contracts traded today, equating to about 1.5 million shares, suggesting strong bullish sentiment among investors at this price level.
- Super Micro Options Volume: Super Micro Computer Inc has recorded an options volume of 215,773 contracts today, representing approximately 21.6 million underlying shares, which is 86.2% of its average daily trading volume of 25 million shares over the past month, reflecting high investor activity in its stock.
- Significant Contracts: For SMCI, the $34.50 strike call option has seen 27,205 contracts traded today, amounting to around 2.7 million shares, indicating strong market interest at this price point, which could influence future stock price movements.
See More
Boxer Capital Acquires New Stake in Terns Pharmaceuticals
- New Investment Disclosure: On February 17, 2026, Boxer Capital Management disclosed its new investment in Terns Pharmaceuticals, acquiring 375,000 shares valued at approximately $15.15 million, indicating strong confidence in the company's future prospects.
- Significant Ownership: This acquisition brings Boxer Capital's stake in Terns to 3.32%, representing a notable position within its $456.88 million in 13F reportable assets under management, reflecting a strategic focus on the biopharmaceutical sector.
- Outstanding Stock Performance: As of February 17, 2026, Terns' shares were priced at $39.58, marking an impressive 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, showcasing strong market recognition of its small-molecule therapies.
- Broad Market Potential: Terns focuses on developing small-molecule therapies targeting non-alcoholic steatohepatitis (NASH) and obesity, with several candidates in clinical trials, poised for value creation through commercialization or out-licensing, addressing urgent market needs for new therapies.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Share Reduction Transaction: According to a SEC filing dated February 17, 2026, ORBIMED Advisors LLC sold 5,409,671 shares of Terns Pharmaceuticals for approximately $125 million, indicating a potential decrease in confidence regarding the company's future prospects.
- Holding Changes: Following this sale, ORBIMED retains 2,153,300 shares of Terns, with a value decrease of $30.20 million, reflecting fluctuations in market expectations for its clinical pipeline.
- Market Performance: As of February 17, 2026, Terns' stock price stood at $39.58, marking an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, showcasing strong market confidence in its biotech potential.
- Investor Focus: With upcoming clinical data releases, investors should monitor Terns' cash flow and trial results to assess whether its pipeline justifies the current high valuation, especially since robust data is crucial for sustaining valuation in the biotech sector.
See More
ORBIMED Reduces Stake in Terns Pharmaceuticals
- Stake Reduction Size: ORBIMED Advisors LLC disclosed in an SEC filing on February 17, 2026, that it reduced its stake in Terns Pharmaceuticals by 5,409,671 shares, with an estimated transaction size of $125.01 million, reflecting a cautious outlook on the company's future prospects.
- Position Value Change: Following this transaction, ORBIMED's position in Terns decreased to 2,153,300 shares, with a value drop of $30.20 million, indicating the market's sensitivity to fluctuations in the company's stock price.
- Asset Management Proportion: After the reduction, Terns now represents 1.78% of ORBIMED's reportable AUM, falling outside the top five holdings, which suggests a diminished significance in the investment portfolio.
- Market Performance Comparison: As of February 17, 2026, Terns' stock price stood at $39.58, reflecting an 858.4% increase over the past year, significantly outperforming the S&P 500 by 862.96 percentage points, demonstrating strong market confidence in its clinical pipeline.
See More
